Literature DB >> 10579919

Signal transduction in the erythropoietin receptor system.

D M Wojchowski1, R C Gregory, C P Miller, A K Pandit, T J Pircher.   

Abstract

Events relayed via the single transmembrane receptor for erythropoietin (Epo) are essential for the development of committed erythroid progenitor cells beyond the colony-forming unit-erythroid stage, and this clearly involves Epo's inhibition of programmed cell death (PCD). Less well resolved, however, are issues regarding the precise nature of Epo-dependent antiapoptotic mechanisms, the extent to which Epo might also promote mitogenesis and/or terminal erythroid differentiation, and the essential vs modulatory nature of certain Epo receptor cytoplasmic subdomains, signal transducing factors, and downstream pathways. Accordingly, this review focuses on the following aspects of Epo signal transduction: (1) Epo receptor/Jak2 activation mechanisms; (2) the critical vs dispensable nature of (P)Y sites and SH2 domain-encoding effectors in survival, growth, and differentiation responses; (3) primary mechanisms by which Epo inhibits PCD; (4) the integration of signals relayed by coexpressed and possibly directly interacting cytokine receptors; and (5) predictions regarding effector function which are provided by the association of certain primary and familial polycythemias with mutated human Epo receptor forms. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579919     DOI: 10.1006/excr.1999.4673

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  47 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

Review 2.  Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease.

Authors:  Betty S Pace; Li Liu; Biaoru Li; Levi H Makala
Journal:  Exp Biol Med (Maywood)       Date:  2015-08

Review 3.  Angiogenesis, neurogenesis and brain recovery of function following injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Curr Opin Investig Drugs       Date:  2010-03

Review 4.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

5.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Authors:  Xiaohui Lu; Ross Levine; Wei Tong; Gerlinde Wernig; Yana Pikman; Sara Zarnegar; D Gary Gilliland; Harvey Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 6.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

Review 7.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Functional conservation of erythropoietin signaling in zebrafish.

Authors:  Noëlle Paffett-Lugassy; Nelson Hsia; Paula G Fraenkel; Barry Paw; Irene Leshinsky; Bruce Barut; Nathan Bahary; Jaime Caro; Robert Handin; Leonard I Zon
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

9.  JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells.

Authors:  A C Breggia; D M Wojchowski; J Himmelfarb
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

10.  beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

Authors:  Luca Melchiori; Sara Gardenghi; Stefano Rivella
Journal:  Adv Hematol       Date:  2010-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.